IOVA vs MRK
IOVA: Iovance is a pioneer in tumor infiltrating lymphocyte (TIL) cell therapy, offering the first one-time, individualized T cell treatment for advanced solid tumor cancers. MRK: Merck & Co. is a leading global biopharmaceutical firm dedicated to delivering life-saving vaccines and innovative therapeutic medicines for major disease areas.
Side-by-side fundamentals
| Metric | IOVA | MRK | Edge |
|---|---|---|---|
| Price as of 2026-08-21 close | $8.29 | $152.55 | |
| Market cap as of 2026-08-24 | $3.8B | $376.4B | |
| P/E as of 2026-08-24 | n/a | 103.86 | |
| PEG as of 2026-08-24 | n/a | 4.91 | |
| Net margin as of 2026-08-24 | -89.1% | +4.8% | MRK higher |
| Gross margin as of 2026-08-24 | +48.4% | +77.3% | MRK higher |
| Operating margin as of 2026-08-24 | -92.7% | +9.6% | MRK higher |
| ROE as of 2026-08-24 | -40.5% | +17.9% | MRK higher |
| ROA as of 2026-08-24 | -31.6% | +7.0% | MRK higher |
| Debt / equity as of 2026-08-24 | 0.00 | 1.07 | IOVA lower |
| Revenue growth (YoY) as of 2026-08-24 | +34.5% | +4.6% | IOVA higher |
| Revenue CAGR (3y) SEC XBRL | +1388.7% | +3.1% | IOVA higher |
| Dividend yield as of 2026-08-24 | n/a | +2.9% | |
| Dividend streak (yrs) SEC XBRL | n/a | 5 | |
| Beta as of 2026-08-24 | 0.85 | 0.22 | |
| 1-year return as of 2026-08-21 close | +226.4% | +77.2% | IOVA higher |
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.